非布司他治疗慢性肾脏病早中期和晚期患者的疗效安全性研究

Effect and Safety Study of Febuxostat in Treatment of Early,Middle and Late Stage Patients with Chronic Kidney Disease

目的分析非布司他在用于慢性肾病早中期和晚期治疗时的临床疗效和安全性。方法选取2021年10月—2022年10月本院收治的90例慢性肾脏疾病伴高尿酸血症患者为研究对象,并根据病情不同分为早中期组(2~3期,50例)和晚期组(4~5期,40例),所有患者均在常规治疗基础上口服非布司他进行治疗,观察两组患者治疗前后各项观察指标水平。结果两组患者临床治疗总有效率和不良反应发生率基本接近(P>0.05),且治疗后两组患者的SUA、Scr、eGFR、TC、TG等生化指标均较治疗前明显改善(P<0.05)。结论非布司他在针对早中期及晚期慢性肾脏疾病合并高尿酸血症患者的临床治疗中,展现出显著的效果,能够有效降低患者的尿酸水平,从而达到保护肾脏的效果。同时,该药物在应用中不良反应发生率较低,确保了治疗的安全性和可靠性。

Objective To analyze clinical effect and safety of febuxostat in early,middle,and late treatment of chronic kidney disease.Methods The paper chose 90 patients with chronic kidney disease in our hospital from 2021 to 2022,and divided them into early to mid stage group(2~3 stages,50 cases)and late stage group(4~5 stages,40 cases)based on different conditions.All cases were treated with oral febuxostat on the basis of routine treatment,levels of various observation indicators before and after treatment were observed in both groups.Results Total effective rate and incidence of adverse reactions in clinical treatment of two groups were basically similar(P>0.05),and biochemical indicators of SUA,Scr,eGFR,TC,TG,etc.between two groups were significantly better after treatment than before(P<0.05).Conclusion Febuxostat can reduce uric acid levels and protect the kidneys of patients with early,middle,and late chronic kidney disease and hyperuricemia effectively,with lower incidence of adverse reactions.